Advertisement
BCRX vs ROIV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and ROIV is a Buy.
BCRX's Indicator enters downward trend
The Aroon Indicator for BCRX entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 201 similar instances where the Aroon Indicator formed such a pattern. In 161 of the 201 cases the stock moved lower. This puts the odds of a downward move at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCRX as a result. In 76 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for BCRX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 40 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BCRX's RSI Oscillator exited the oversold zone, 31 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.376) is normal, around the industry mean (10.407). P/E Ratio (-5.763) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (2.097) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. BCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Momentum Indicator for ROIV turns positive, indicating new upward trend
ROIV saw its Momentum Indicator move above the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 76 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ROIV's RSI Oscillator exited the oversold zone, 18 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for ROIV just turned positive on October 21, 2026. Looking at past instances where ROIV's MACD turned positive, the stock continued to rise in 45 of 57 cases over the following month. The odds of a continued upward trend are 79%.
ROIV moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +7.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where ROIV advanced for three days, in 230 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for ROIV crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ROIV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
ROIV broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ROIV entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.393) is normal, around the industry mean (2.973). ROIV's P/E Ratio (-104.028) is considerably lower than the industry average of (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. ROIV's P/S Ratio (3333.333) is slightly higher than the industry average of (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. ROIV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
BCRX | ROIV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 13 | |
SMR RATING 1..100 | 100 | 92 | |
PRICE GROWTH RATING 1..100 | 62 | 39 | |
P/E GROWTH RATING 1..100 | 98 | 54 | |
SEASONALITY SCORE 1..100 | 90 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ROIV's Valuation (3) in the null industry is in the same range as BCRX (14) in the Biotechnology industry. This means that ROIV’s stock grew similarly to BCRX’s over the last 12 months.
ROIV's Profit vs Risk Rating (13) in the null industry is significantly better than the same rating for BCRX (100) in the Biotechnology industry. This means that ROIV’s stock grew significantly faster than BCRX’s over the last 12 months.
ROIV's SMR Rating (92) in the null industry is in the same range as BCRX (100) in the Biotechnology industry. This means that ROIV’s stock grew similarly to BCRX’s over the last 12 months.
ROIV's Price Growth Rating (39) in the null industry is in the same range as BCRX (62) in the Biotechnology industry. This means that ROIV’s stock grew similarly to BCRX’s over the last 12 months.
ROIV's P/E Growth Rating (54) in the null industry is somewhat better than the same rating for BCRX (98) in the Biotechnology industry. This means that ROIV’s stock grew somewhat faster than BCRX’s over the last 12 months.
| BCRX | ROIV | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 86% | 1 day ago 78% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 76% |
| Momentum ODDS (%) | 1 day ago 80% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 73% | 1 day ago 79% |
| TrendWeek ODDS (%) | 1 day ago 81% | 1 day ago 76% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 73% |
| Advances ODDS (%) | N/A | 1 day ago 78% |
| Declines ODDS (%) | 2 days ago 79% | 10 days ago 70% |
| BollingerBands ODDS (%) | N/A | 1 day ago 65% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 78% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCRX’s FA Score shows that 1 FA rating(s) are green while ROIV’s FA Score has 2 green FA rating(s).
- BCRX’s FA Score: 1 green, 4 red.
- ROIV’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCRX’s TA Score shows that 2 TA indicator(s) are bullish while ROIV’s TA Score has 6 bullish TA indicator(s).
- BCRX’s TA Score: 2 bullish, 4 bearish.
- ROIV’s TA Score: 6 bullish, 4 bearish.
Price Growth
BCRX (@Pharmaceuticals: Generic) experienced а -2.99% price change this week, while ROIV (@Biotechnology) price change was +10.02% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.00%. For the same industry, the average monthly price growth was -9.86%, and the average quarterly price growth was +9.31%.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
BCRX is expected to report earnings on Nov 02, 2026.
ROIV is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-3.00% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ROIV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.
| Ticker / NAME | Correlation To ROIV | 1D Price Change % | ||
|---|---|---|---|---|
| ROIV | 100% | +1.77% | ||
| IMVT - ROIV | 62% Loosely correlated | +2.54% | ||
| IMTX - ROIV | 43% Loosely correlated | -1.95% | ||
| AXON - ROIV | 43% Loosely correlated | +2.98% | ||
| DNTH - ROIV | 42% Loosely correlated | +0.55% | ||
| MLYS - ROIV | 41% Loosely correlated | +1.75% | ||
More | ||||